TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20523092
Drug: Oxaliplatin 70
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 70 mg/m(2) on days 1 and 15, irinotecan 100 mg/m(2) on days 8 and 22, capecitabine (dose levels 1-5, between 800 and 1,600 mg/m(2)) on days 1-29 every 5 weeks.
Study: 20523092
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at the recommended dose of 1,400 mg/m(2) daily.
Study: 20525721
Drug: Trimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodality therapy (induction chemotherapy with cisplatin 75 mg·m⁻² and pemetrexed 500 mg·m⁻², followed by extrapleural pneumonectomy and post-operative radiotherapy at 54 Gy, 30 fractions)
Study: 20529243
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (simvastatin and ezetimibe)
Study: 20530034
Drug: Riociguat 1.0-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat 1.0-2.5 mg t.i.d. titrated according to systemic systolic blood pressure (SBP)
Study: 20530048
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg·m⁻²) plus valproic acid
Study: 20530284
Drug: Radioimmunotherapy (RIT)
Normalized name: mumps virus vaccine live, RIT-4385 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic hematopoietic cell transplantation (HCT)
Study: 20538956
Drug: mRNA content
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA content of peroxisome proliferator-activated receptor γ coactivator 1-α in critically ill patients.
Study: 20545713
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration (200 mL of hydroxyethyl starch, HES 130/0.4)
Study: 20545869
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in device size (1-cc)
Study: 20549827
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (letrozole or exemestane)
Study: 20551376
Drug: BACOPP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BACOPP regimen (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) administered in 6 to 8 cycles; 75% of treatment courses were administered according to protocol
Study: 20551454
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg for 2 weeks)
Study: 20555351
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB radiation therapy (NB-UVB) for 6 weeks
Study: 20555351
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB radiation therapy (NB-UVB)
Study: 20559034
Drug: Single vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccination with a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Study: 20560883
Drug: Rectal luminal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal luminal lactate concentration
Study: 20560883
Drug: Rectal-arterial difference
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal-arterial difference of lactate concentration
Study: 20560883
Drug: Blood pressure,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure, noradrenaline dose, central venous oxygen saturation
Study: 20562526
Drug: Chloroquine or
Normalized name: chloroquine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine or other autophagy/lysosome inhibitors
Study: 20564111
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tumor diameter >5 cm and N+
Study: 20564750
Drug: Multilevel surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel surgical treatment (uvulopalatopharyngoplasty, tonsillectomy, genioglossus advancement, with or without hyoid suspension)
Study: 20564750
Drug: Multilevel surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel surgical treatment
Study: 20573151
Drug: Acupuncture (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (twice on the same day at acupuncture point GV20 and bilaterally at points BL67, LI4 and SP6)
Study: 20576011
Drug: IVIG administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIG administration
Study: 20579630
Drug: 20% topical
Normalized name: Urea 20% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% topical autologous serum
Study: 20579630
Drug: No use
Approvals — FDA: no, EMA: no, PMDA: no
Description: No use of topical autologous serum
Study: 20581689
Drug: Fibrinogen levels
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen levels in the highest tertile (>406 mg/dL)
Study: 20581689
Drug: Fibrinogen (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen (as a linear variable) per 100 mg/dL increase
Study: 20582937
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m(2) with VXLD chemotherapy
Study: 20582937
Drug: Bortezomib 1
Normalized name: bortezomib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1 mg/m(2) with VXLD chemotherapy
Study: 20582937
Drug: Bortezomib with
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib with VXLD chemotherapy
Study: 20584275
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy (N = 12)
Study: 20584542
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once daily until PD or unacceptable toxicity
Study: 20591191
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14), 2 capsules a day for 6-12 weeks, up to the 24th-25th week of gestation.
Study: 20594195
Drug: Bendamustine 90
Normalized name: bendamustine 90 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 90 mg/m²
Study: 20594195
Drug: Bendamustine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 120 mg/m²
Study: 20595284
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg subcutaneous injections every other week
Study: 20599188
Drug: GSK598809 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK598809 (selective D(3) receptor antagonist)
Study: 20605934
Drug: SU14813 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU14813 (200 mg/day on schedule 4/1)
Study: 20605934
Drug: SU14813 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU14813 (100 mg/day with continuous daily dosing)
Study: 20606544
Drug: Rituximab administered
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab administered intravenously at 375 mg/m2 on each of 4 consecutive weeks with conventional immunotherapy (Group I and II)
Study: 20606544
Drug: Rituximab administered
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab administered intravenously at 375 mg/m2 on each of 4 consecutive weeks without conventional immunotherapy (Group III)
Study: 20606544
Drug: Rituximab dosing
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab dosing based on body weight
Study: 20606683
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor therapy (AI); specific dosage and duration not mentioned.
Study: 20606683
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without AIMSS); specific dosage and duration not mentioned.
Study: 20608766
Drug: Baseline IP-10
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline IP-10 < 150 pg/ml
Study: 20609468
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg twice daily
Study: 20609706
Drug: Sirna-027 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirna-027 (100 and 200 microg doses)
Study: 20610186
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg daily for 90 days
Study: 20617532
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti-Sa antibodies at inclusion, especially at higher titers
Study: 20617532
Drug: Low titer
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low titer of any particular antibody
Study: 20617532
Drug: Reversion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversion of RF and anti–CCP-2 antibodies
Study: 20617532
Drug: Initial positivity
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial positivity for RF and anti–CCP-2 antibodies
Study: 20617532
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti-Sa antibodies
Study: 20619378
Drug: 240 microg
Normalized name: Latanoprostene bunod 240 microgram/mL eye drops solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 microg dose
Study: 20624109
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (three doses of 4 g)
Study: 20626754
Drug: Bendamustine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (120 mg/m² on days 1-2 of a 21-day cycle, for up to six cycles)
Study: 20630061
Drug: Temsirolimus administered
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus administered intravenously at 25 mg weekly (Study A)
Study: 20630061
Drug: Everolimus administered
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus administered orally at 30 mg weekly and erlotinib at 150 mg daily (Study B)
Study: 20633428
Drug: ECT (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT (6 bilateral treatments, outpatient, twice-weekly)
Study: 20634373
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m(2) on days 1, 29, 57 and 85; Fludarabine orally, 40 mg/m(2) on days 1-5, 29-34, 57-61 and 85-89
Study: 20634373
Drug: Fludarabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine and rituximab combination therapy
Study: 20634785
Drug: Diannexin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diannexin treatment
Study: 20636419
Drug: Inadequate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate or no antimicrobial treatment at origin
Study: 20638196
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of CHOP chemotherapy and radiation to a dose of 45 Gy in 25 fractions using a shrinking field technique
Study: 20650686
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression
Study: 20650686
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy
Study: 20651074
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg/d with a 3-month low-dose prednisone taper
Study: 20653948
Drug: IMP321 (LAG-3Ig)
Normalized name: Anti-lag-3 monoclonal antibody regn3767
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP321 (LAG-3Ig) administered subcutaneously every two weeks for 24 weeks (12 injections) alongside paclitaxel (80 mg/m2 weekly for 3 weeks out of 4)
Study: 20659883
Drug: Initial serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial serum glucose level >140 mg/dl
Study: 20660050
Drug: Thymidine analogs
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymidine analogs (iododeoxyuridine or bromodeoxyuridine) administered 8 days to 4 years prior to death.
Study: 20662793
Drug: Gemcitabine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine combined with carboplatin (i.v. gemcitabine at 1000 mg/m² on days 1 and 8, and i.v. carboplatin at AUC 5 on day 1 of a 21-day cycle)
Study: 20663944
Drug: Oral busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral busulfan 12 mg/kg plus melphalan 140 mg/m2
Study: 20663944
Drug: Melphalan 200
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 200 mg/m2
Study: 20664181
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for MCI patients combining psychoeducation, cognitive rehabilitation, and cognitive-behavioral therapy.
Study: 20666569
Drug: Low-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ASA (75-325 mg daily)
Study: 29619769
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (specifics not provided)
Study: 20668228
Drug: Preparative chemotherapy
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative chemotherapy regimen
Study: 20671408
Drug: Metformin (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1250 mg/day)
Study: 20675064
Drug: Pulsed-dose-rate (PDR)
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed-dose-rate (PDR) brachytherapy, 49.8 Gy in 83 consecutive fractions of 0.6 Gy each hour, total treatment time 3 to 4 days.
Study: 20675064
Drug: High-dose-rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate (HDR) brachytherapy, 32 Gy in eight fractions of 4 Gy, twice daily.
Study: 20675064
Drug: Antihormonal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihormonal treatment (AHT) applied (91% of patients)
Study: 20675064
Drug: No antihormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihormonal treatment (AHT not applied, 9% of patients)
Study: 20677285
Drug: Early allograft
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early allograft dysfunction (EAD) defined by bilirubin >or=10mg/dL on day 7, INR >or=1.6 on day 7, and ALT/AST >2000 IU/L within the first 7 days.
Study: 20681993
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) in obese men
Study: 20683637
Drug: 17-AAG (17-allylamino-17-demethoxygeldanamycin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-AAG (17-allylamino-17-demethoxygeldanamycin), administered weekly, intravenous
Study: 20685491
Drug: Calcium 1200
Normalized name: Premier Value Calcium 1200 + D3 Extended-Release Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1200 to 2000 mg/d
Study: 20689350
Drug: Receptive music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receptive music therapy
Study: 20696979
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with abnormal anticardiolipin antibody levels
Study: 20697802
Drug: Sagopilone 16
Normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sagopilone 16 mg/m²
Study: 20697802
Drug: Sagopilone 22
Normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sagopilone 22 mg/m²
Study: 20697802
Drug: Sagopilone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sagopilone (both doses)
Study: 20698927
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid plus vitamin B12 treatment (0.8 mg folic acid, 0.4 mg vitamin B12, 40 mg vitamin B6)
Study: 20698927
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid plus vitamin B12 treatment
Study: 20701823
Drug: Quetiapine (dose-dependent)
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine (dose-dependent)
Study: 20701823
Drug: Quetiapine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (high doses)
Study: 20701823
Drug: Quetiapine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (low doses)
Study: 20702138
Drug: FOLFOXIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI plus bevacizumab (irinotecan 165 mg/m², oxaliplatin 85 mg/m², folinate 200 mg/m², fluorouracil 3200 mg/m² for 48 h continuous infusion)
Study: 20702138
Drug: FOLFOXIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI plus bevacizumab (induction treatment for a maximum of 6 months, followed by maintenance treatment with bevacizumab 5 mg/kg every 2 weeks)
Study: 20702138
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with bevacizumab (5 mg/kg every 2 weeks)
Study: 20708849
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a total dose of 60 Gy in three fractions for peripheral lesions and four fractions for central lesions.
Study: 20710052
Drug: Etravirine 400
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 400 mg once daily with tenofovir disoproxil fumarate/emtricitabine 300/200 mg once daily from days 1-14; darunavir/ritonavir 800/100 mg once daily added on days 15-28
Study: 20710052
Drug: Etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 200 mg twice daily (post-hoc analysis)
Study: 20710088
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment program including a 3-phase progressive strengthening program, manual stretching, thrust and nonthrust manipulation to the shoulder and spine, patient education, activity modification, and a daily home exercise program of stretching and strengthening.
Study: 20710088
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment program
Study: 20712386
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 20 mg/day, uptitrated to OM 40 mg/day, OM/HCTZ 40/12.5 mg/day, and OM/HCTZ 40/25 mg/day as needed
Study: 20712386
Drug: Olmesartan medoxomil/hydrochlorothiazide
Normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40/25 mg/day
Study: 20713833
Drug: Liquor carbonis
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquor carbonis distillate solution
Study: 20713962
Drug: Eliglustat tartrate
Normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eliglustat tartrate 50 or 100 mg twice daily for 2 years
Study: 20716591
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg) plus Erlotinib (200 mg/day for non-EIAEDs; 500 mg/day for EIAEDs)
Study: 20716591
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg) plus Erlotinib
Study: 20718769
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) levels
Study: 20719837
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH) therapy
Study: 20719839
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment (hydrocortisone 26%, prednisolone 43%, dexamethasone 19%, combination 10%)
Study: 20721537
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 to 30 mg/day)
Study: 20724537
Drug: M-dex +
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-dex + lenalidomide 15 mg/day
Study: 20724742
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of albuterol plus tiotropium
Study: 20725912
Drug: Colesevelam treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam treatment
Study: 20727190
Drug: Multipeptide vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multipeptide vaccine in incomplete Freund's adjuvant (IFA)
Study: 20729251
Drug: Decision aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision aid intervention to inform and support the choice between tube feeding and assisted oral feeding
Study: 20730365
Drug: Aquatic physical
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic physical therapy for 10 minutes, involving movements to stimulate flexor posture and postural organization.
Study: 20731625
Drug: 4 h
Normalized name: Type 4 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 h graded infusion of intralipid (20%)/heparin